Skip to main content

Corcept Therapeutics Inc (CORT) Stock

Corcept Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Corcept Therapeutics Inc (CORT), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $83.90. Over the past 52 weeks, it has ranged between $42.01 and $117.33. This places the current price at 71.5% of its 52-week high and 99.7% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 71.16, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $72.48 by 15.76%. Similarly, it is above its 200-day moving average of $67.51 by 24.28%. The MACD histogram is 1.03, indicating bullish momentum (MACD Line: 3.45, Signal Line: 2.42). There are currently 2 active alerts set for CORT by users.

Market Cap

$8.84B

52-Week High

$117.33

-28.49% from high

52-Week Low

$42.01

+99.71% from low

Avg Daily Volume

1,111,751

100-day average

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

74.88

Above market average

Forward P/E

24.10

Earnings expected to grow

PEG Ratio

0.61

Potentially undervalued

Price to Book

13.71

EV/EBITDA

80.72

EPS (TTM)

$1.12

Price to Sales

12.34

Beta

0.29

Less volatile than market

How is CORT valued relative to its earnings and growth?
Corcept Therapeutics Inc trades at a P/E ratio of 74.88, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 24.10 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.61 suggests the stock may be undervalued relative to its growth rate.
What is CORT's risk profile compared to the market?
With a beta of 0.29, Corcept Therapeutics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 13.71 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

18.70%

Operating Margin

13.70%

Return on Equity

21.70%

Return on Assets

8.36%

Revenue Growth (YoY)

18.70%

Earnings Growth (YoY)

-9.40%

How profitable and efficient is CORT's business model?
Corcept Therapeutics Inc achieves a profit margin of 18.70%, meaning it retains $18.70 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 13.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 21.70% and ROA at 8.36%, the company generates strong returns on invested capital.
What are CORT's recent growth trends?
Corcept Therapeutics Inc's revenue grew by 18.70% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 9.40% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Shares Outstanding

105.37M

Book Value/Share

$6.04

Asset Type

Common Stock

What is CORT's market capitalization and position?
Corcept Therapeutics Inc has a market capitalization of $8.84B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 105.37M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does CORT's price compare to its book value?
Corcept Therapeutics Inc's book value per share is $6.04, while the current stock price is $83.90, resulting in a price-to-book (P/B) ratio of 13.89. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$135.25

61.20% upside potential

Analyst Recommendations

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

How reliable are analyst predictions for CORT?
4 analysts cover CORT with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $135.25 implies 61.2% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on CORT?
Current analyst recommendations:2 Strong Buy, 2 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 27, 2025, 06:58 PM

Earnings Dates

Upcoming Earnings

Q3

Oct 29, 2025

Est. EPS: $0.17

In 29 days

Recent Earnings History

DateQuarterEstimated EPSActual EPSSurprise
Jul 31, 2025Q2$0.19$0.29+55.6%
May 5, 2025Q1$0.14$0.17+18.8%
Feb 26, 2025Q4$0.42$0.26-38.6%
Oct 30, 2024Q3$0.28$0.41+46.4%
Jul 29, 2024Q2$0.23$0.32+39.1%
May 1, 2024Q1$0.22$0.25+13.6%
Feb 15, 2024Q4$0.26$0.28+7.7%
Nov 1, 2023Q3$0.22$0.28+27.3%

Technical Indicators

RSI (14-day)

71.16

Overbought

50-Day Moving Average

$72.48

15.76% above MA-50

200-Day Moving Average

$67.51

24.28% above MA-200

MACD Line

3.45

MACD Signal

2.42

MACD Histogram

1.03

Bullish

What does CORT's RSI value tell investors?
The RSI (Relative Strength Index) for CORT is currently 71.16, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret CORT's MACD and moving average crossovers?
MACD analysis shows the MACD line at 3.45 above the signal line at 2.42, with histogram at 1.03. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($72.48) is above the 200-day MA ($67.51), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Sep 30, 2025, 12:42 AM

Active Alerts

Alert Condition
RSI Threshold Cross
Threshold
50
Created
Sep 27, 2025, 06:58 PM
Alert Condition
Forward P/E falls below
Threshold
22 x
Created
Sep 27, 2025, 06:58 PM

Stay Ahead of the Market with Corcept Therapeutics Inc Alerts

Set up price alerts for Corcept Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.